Managing Psoriasis in Patients With Obesity: A Multidisciplinary Approach
Transcript:
Patients with psoriatic disease and comorbid obesity are indeed more likely to have involvement of challenging to treat areas. Palms and soles 3.5 times, higher prevalence of patients with comorbid obesity, inverse psoriasis 2.2 times, nails 1.8 times.
So, what's our role in managing our patients who have this background obesity? And this is a really big deal and I think it's part of our conversation today.
We want to inform patients regarding the association between the metabolic syndrome inclusive of obesity and their components and psoriatic disease. We want to advise patients to practice a healthy lifestyle to show that the patient is engaged with their PCP and communicate with the patient's PCP to have them evaluated appropriately for obesity and other comorbidities.
You know, patients with psoriasis and comorbidities, they tend to have more difficulties in responding to biologic therapies in general. And clearly, we know that weight loss is associated with a reduction in psoriasis severity.
And I'll add in there that we know that, you know, bariatric surgery has been studied in the number of clinical trials and has been shown to reduce the impact of psoriatic disease, both skin and then the joints.
I think we need our primary care partners to participate to get these patients on weight loss programs and we really need to collaborate with them and we need to drive some of the education to them as well too, because I'm not so sure that they're all aware that all those components of the metabolic syndrome are related to driving that inflammation in our patients with psoriatic disease.
References:
- https://wwwn.cdc.gov/nchs/nhanes/Default.aspx (Accessed January 30, 2024).
- Data on file. Lilly USA.
- Scher JU, et al. Nat Rev Rheumatol. 2019;15(3):153-166.
- Rathod A, et al. Indian Dermatol Online J. 2022;13(5):606-610.
- Herron MD, et al. Arch Dermatol. 2005;141(12):1527-1534.
- Czarnecka A, et al. Medicina (Kaunas). 2023;59(11):2006.
- Elmets CA, et al. J Am Acad Dermatol. 2019;80(4):1073-1113.
- Pirro F, et al. Clin Drug Investig. 2021;41:917-925.
- Jensen P, et al. JAMA Dermatol. 2013;149(7):795-801
- Egeberg A, et al. JAMA Surg. 2017;152(4):344-349.
- Gallo G, et al. Rev Recent Clin Trials. 2018;13(3):176-183.
